Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

37.40
-0.2000-0.53%
Post-market: 37.34-0.0600-0.16%19:30 EDT
Volume:1.60M
Turnover:59.67M
Market Cap:5.03B
PE:-10.74
High:38.14
Open:37.70
Low:36.86
Close:37.60
52wk High:49.70
52wk Low:10.46
Shares:134.37M
Float Shares:129.97M
Volume Ratio:0.66
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.47
PE(LYR):-18.16

Loading ...

Definium Therapeutics prices upsized public offering at USD 700 million

Reuters
·
Jun 24

Definium Therapeutics - Prices Public Offering of 20.59 Mln Shares at $34 per Share

THOMSON REUTERS
·
Jun 24

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

THOMSON REUTERS
·
Jun 24

Definium Therapeutics price target raised to $57 from $37 at Baird

TIPRANKS
·
Jun 23

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys

Reuters
·
Jun 23

Definium Therapeutics Inc : Canaccord Genuity Raises Target Price to $60 From $38

THOMSON REUTERS
·
Jun 23

Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ

Dow Jones
·
Jun 23

Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD

Reuters
·
Jun 23

Small U.S. Stocks Close Mixed As Definium Therapeutics Leads, Butterfly Network Lags

Dow Jones
·
Jun 23

Definium Therapeutics Reports $500 Million Public Offering

MT Newswires Live
·
Jun 23

Definium Therapeutics offers to sell $500M in common stock

TIPRANKS
·
Jun 23

Definium Therapeutics plans USD 500 million follow-on stock offering

Reuters
·
Jun 23

Definium Therapeutics, Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
Jun 23

Definium Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 23

Top Midday Gainers

MT Newswires Live
·
Jun 23

Canaccord ups Definium Therapeutics target to $60, calls DT120 ‘solid contender’

TIPRANKS
·
Jun 23

Definium Therapeutics rises 55.9%

TIPRANKS
·
Jun 23

RBC Capital Adjusts Price Target on Definium Therapeutics to $57 From $36, Maintains Outperform Rating

MT Newswires Live
·
Jun 23

Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk

TIPRANKS
·
Jun 22

Definium Therapeutics price target raised to $60 from $40 at Oppenheimer

TIPRANKS
·
Jun 22